Rome V Functional Esophageal Disorders: Gastroenterology | May 2026

Rome V reframes functional esophageal disorders as esophageal disorders of gut–brain interaction (E-DGBI), emphasizing that these syndromes arise from altered esophageal sensory signaling and central perceptual processing rather than occult structural disease. The defining clinical principle is that patients present with heartburn, chest pain, globus, or dysphagia, but without explanatory structural pathology, major esophageal motor disorders, or pathologic reflux. Rome V’s most important conceptual advance is the formal integration of Lyon Consensus 2.0 for reflux assessment and Chicago Classification v4.0 (CCv4.0) for motility, making the diagnosis of E-DGBI more physiologically rigorous and less exclusionary by approximation.

This update substantially improves clinical precision. Rather than labeling persistent esophageal symptoms as “functional” after a normal endoscopy alone, Rome V now requires systematic exclusion of mucosal disease, GERD, eosinophilic esophagitis (EoE), and major motor disorders using contemporary physiologic testing. This is a major practical shift because it reduces both underdiagnosis of subtle esophageal disease and overdiagnosis of functional syndromes. The central pathophysiologic model is now explicit: symptom generation reflects esophageal hypersensitivity, hypervigilance, altered autonomic regulation, and maladaptive brain–gut processing, often amplified by psychosocial stressors and symptom-specific anxiety.

Functional Chest Pain: A More Rigorous Diagnosis of Exclusion

Rome V defines functional chest pain as recurrent retrosternal chest pain of presumed esophageal origin, distinct from heartburn and unexplained by GERD, mucosal disease, or major motility disorders. The major practical refinement is that this diagnosis now requires exclusion using Lyon 2.0 reflux thresholds, CCv4.0 motility criteria, and selective mucosal biopsy rather than broad empiricism. Importantly, cardiac disease must still be excluded first, because symptom pattern alone cannot reliably distinguish esophageal from cardiac pain.

A key Rome V change is that esophageal biopsies are no longer required for all patients with chest pain, unlike Rome IV. Biopsies are now recommended only when chest pain is meal-related, where occult EoE may mimic pain-predominant disease. This reduces unnecessary biopsy burden while preserving diagnostic sensitivity in clinically relevant cases. Rome V also clarifies that ineffective esophageal motility (IEM) is not exclusionary, while conclusive EGJOO, achalasia, DES, and hypercontractile esophagus remain exclusionary.

Mechanistically, Rome V strongly anchors functional chest pain in esophageal hypersensitivity and altered central pain processing. Up to 75% of patients demonstrate heightened sensitivity to esophageal distension, and psychiatric comorbidity—particularly anxiety, depression, and somatization—is highly prevalent and clinically relevant. Treatment therefore shifts away from acid suppression and toward neuromodulation and behavioral therapy. TCAs, SNRIs, trazodone, and selected SSRIs remain the pharmacologic backbone, while GI-CBT, gut-directed hypnotherapy, and biofeedback are now explicitly recognized as evidence-based therapeutic options rather than adjunctive alternatives.

Functional Heartburn: More Stringent Separation From GERD

Rome V retains functional heartburn as a distinct diagnosis but makes its boundaries with GERD more rigorous. Functional heartburn is now defined as retrosternal burning that persists despite optimized antisecretory therapy, with no evidence of GERD, EoE, EGJ dysfunction, or major motility disorder. The most important clinical advance is a sharper physiologic distinction between functional heartburn and GERD using Lyon 2.0 criteria, especially prolonged reflux monitoring and adjunctive impedance metrics.

Rome V reinforces that a normal endoscopy is insufficient to exclude GERD. Diagnosis now requires objective reflux exclusion, ideally with 96-hour wireless pH monitoring off therapy. Functional heartburn is favored when acid exposure remains physiologic and symptom association is negative. Mean nocturnal baseline impedance (MNBI) is now clinically useful: MNBI >2500 Ω supports functional heartburn, whereas low impedance favors GERD. This is a major practical step toward physiologic phenotyping of refractory heartburn.

Therapeutically, Rome V strongly discourages repeated invasive testing and explicitly states that antireflux surgery should be avoided in functional heartburn. This is one of the most practice-changing statements in the document. Management should instead focus on reassurance, reduction of hypervigilance, and neuromodulation. GI-CBT, diaphragmatic breathing, hypnotherapy, and low-dose neuromodulators are emphasized as mechanistically aligned and clinically safer than procedural escalation.

Reflux Hypersensitivity: Preserved but Better Defined

Rome V preserves reflux hypersensitivity but refines its boundaries. This disorder now requires heartburn and/or chest pain with physiologic acid exposure but positive reflux–symptom association, distinguishing it from both GERD and functional heartburn. The critical clinical distinction is that symptoms remain temporally linked to reflux events despite physiologic reflux burden.

Rome V now explicitly excludes regurgitation and belching as qualifying symptoms in isolation, which is clinically important because these symptoms often reflect mechanical or behavioral disorders such as rumination or supragastric belching rather than reflux hypersensitivity. This reduces diagnostic contamination and improves phenotypic precision.

Management remains similar to functional heartburn, but Rome V acknowledges that some patients—particularly those with acid-sensitive esophagus or hiatal hernia—may respond to acid suppression or, selectively, antireflux surgery. However, the dominant therapeutic model remains neuromodulation plus psychogastroenterology rather than acid suppression alone.

Globus: Less Procedural, More Conservative

Rome V retains globus largely unchanged but makes one clinically important correction: the role of gastric inlet patch is substantially de-emphasized. Rome IV was more permissive toward inlet patch ablation; Rome V is more conservative and states that while inlet patch may be relevant in selected patients, evidence supporting ablation remains low quality and should not drive routine intervention.

This change matters clinically because globus is common, benign, and often chronic, yet historically over-investigated and overtreated. Rome V favors a structured but conservative approach: exclude local structural disease and laryngeal pathology, consider a short PPI trial, then proceed toward reassurance and behavioral management if unrevealing. Once GERD and structural disease are excluded, CBT-based psychoeducation, speech therapy, pharyngolaryngeal relaxation, and hypnosis are favored over repeated endoscopy, ablation, or procedural escalation.

Functional Dysphagia: The Most Important Diagnostic Upgrade

Functional dysphagia undergoes the most meaningful diagnostic modernization in Rome V. While Rome IV relied largely on normal endoscopy and HRM, Rome V now recognizes that subtle EGJ dysfunction and impaired distensibility may be missed by conventional testing. Accordingly, functional lumen imaging probe (FLIP) and supportive timed barium esophagram are now explicitly incorporated into the diagnostic framework. This is arguably the most important technical advance in Rome V functional esophageal disorders.

This change has major practical implications. Rome V acknowledges that many patients previously labeled with functional dysphagia under Rome IV likely had subtle EGJ outflow resistance, impaired distensibility, or borderline achalasia physiology that standard manometry failed to detect. FLIP can identify these hidden physiologic abnormalities and therefore reduce false-positive diagnosis of functional dysphagia. As a result, true functional dysphagia becomes a more specific—and likely less common—diagnosis.

Rome V also clarifies that esophageal biopsies are essential in dysphagia, even when mucosa appears normal, because EoE and other inflammatory disorders may be histologically occult. It further reinforces that IEM does not exclude functional dysphagia, whereas achalasia, conclusive EGJOO, DES, and hypercontractile esophagus do. This improves diagnostic discipline and reduces overcalling minor motility findings as causative.

Management remains conservative and phenotype-directed. Reassurance, swallowing modification, and selective neuromodulation remain foundational. However, Rome V also recognizes that selected patients with unexplained solid-food dysphagia may benefit from empiric bougie dilation, especially where subtle proximal mechanical dysfunction is suspected despite negative routine testing. With FLIP integration, this can now be better targeted and more physiologically justified.

Clinical Bottom Line

Rome V significantly modernizes functional esophageal disorders by replacing broad symptom-based exclusion with physiology-driven phenotyping. The most important practical changes are:

formal integration of Lyon 2.0 and Chicago Classification v4.0,

selective rather than routine biopsy in functional chest pain,

stronger physiologic separation of functional heartburn vs reflux hypersensitivity vs GERD,

de-escalation of procedural management in globus, and

incorporation of FLIP as a major diagnostic advance in functional dysphagia.

Collectively, these changes move practice away from empiricism, repeated acid suppression, and procedural overuse, and toward mechanism-based diagnosis, neuromodulation, psychogastroenterology, and precision esophageal physiology. For clinical practice, Rome V is less about renaming functional esophageal disorders and more about redefining them with substantially greater physiologic rigor.